

INTERIM REPORT THIRD QUARTER 2026

Accelerating performance validates our partnership model

Third quarter 2026 (July – September)

- Total revenue amounted to SEK 58.4 (48.4) million, an increase of SEK 10.0 million corresponding to 20.6%.
- Net sales amounted to SEK 55.1 (45.5) million, an increase of SEK 9.7 million corresponding to 21.2%.
Adjusted for currency effects of SEK 1.1 million, net sales increased by 23.6%.
- Operating profit amounted to SEK 6.8 (-6.4) million.
- EBITDA amounted to SEK 17.5 (5.3) million with a margin of 30.0% (10.9%).
- Adjusted EBITDA amounted to SEK 20.0 (5.3) million with a margin of 34.3% (10.9%).
- Net profit for the period amounted to SEK 7.3 (-7.5) million.
- Profit per share, before and after dilution, amounted to SEK 0.25 (-0.21).
- Cash flow from operating activities amounted to SEK 14.0 (-2.8) million corresponding to SEK 0.39 (-0.08) per share.
- Net debt excluding lease liabilities amounted to SEK 64.2 (83.0) million.

The period January – September 2026

- Total revenue amounted to SEK 162.4 (163.2) million, a decrease of SEK 0.8 million corresponding to 0.5%.
- Net sales amounted to SEK 151.6 (152.8) million, a decrease of SEK 1.2 million corresponding to 0.8%.
Adjusted for currency effects of SEK 7.9 million, net sales increased by 4.4%.
- Operating loss amounted to SEK 8.6 (16.3) million.
- EBITDA amounted to SEK 24.3 (19.1) million with a margin of 15.0% (11.7%).
- Adjusted EBITDA amounted to SEK 30.6 (19.1) million with a margin of 18.8% (11.7%).
- Net loss for the period amounted to SEK 6.5 (20.4) million.
- Loss per share, before and after dilution, amounted to SEK 0.14 (0.59).
- Cash flow from operating activities amounted to SEK 18.7 (-13.2) million corresponding to SEK 0.53 (-0.38) per share.

Key figures	Jul-Sep		Jan-Sep		Full year	RTM
	2026	2025	2026	2025	2025	2025/26
Total revenue ¹ ,MSEK	58.4	48.4	162.4	163.2	228.8	227.9
Operating profit/loss ¹ ,MSEK	6.8	-6.4	-8.6	-16.3	-3.3	4.4
EBITDA ² ,MSEK	17.5	5.3	24.3	19.1	43.8	49.0
EBITDA margin ² ,%	30.0	10.9	15.0	11.7	19.1	21.5
Adjusted EBITDA ² ,MSEK	20.0	5.3	30.6	19.1	43.8	55.3
Net profit/loss for the period ¹ ,MSEK	7.3	-7.5	-6.5	-20.4	-7.8	6.0
Earnings per share ¹ ,SEK	0.25	-0.21	-0.14	-0.59	-0.22	0.22
Cash flow from operating activities ¹ ,MSEK	14.0	-2.8	18.7	-13.2	-1.5	30.4
Cash flow from operating activities, per share ² ,SEK	0.39	-0.08	0.53	-0.38	-0.04	0.87
Equity ratio ² ,%	59.8	55.4	59.8	55.4	57.8	59.8
Net debt ² ,MSEK	98.7	128.7	98.7	128.7	118.7	98.7

¹ Defined according to IFRS.

² Alternative performance measure. For definition and reconciliation, see pages 16-17.



CEO statement Q3 2026

Accelerating performance validates our partnership model

We are pleased to report a very strong third quarter, following the solid second quarter, demonstrating the scalability of the partnership business model and the results our execution delivers.

Advancing the building blocks for partnership growth and new partnership generation

Demand for Bactiguard-coated products remained strong, and during the quarter we carried out further commercialization activities together with our partners. We work across the value chain from coating technology through commercialization encompassing process and product development, regulatory approvals and sales & marketing training to help partners bring products successfully to patients.

We continued to advance regulatory programs that support product approvals, market access and future commercialization. Over the past two years we have expanded our regulatory expertise and direct dialogue with authorities, including the FDA, to facilitate an efficient product approval process for partners. Our growing involvement in this work shows how the value we bring to partners increasingly extends beyond the noble metal technology itself. We also strengthened our scientific evidence including new publications. In September we presented new data at leading orthopedic congresses demonstrating both the durability of the coating and the differentiation of the technology, which has no market equivalent.

Within business development, orthopedics remains the area where partner engagement is strongest, reflecting the well-recognized need for infection prevention in implant surgery and increasing focus among payers on the economic burden of infections. During the quarter, we deepened our engagement and made meaningful headway across several initiatives, further reinforcing the significant avenues for future partnership development within this therapeutic area.

Strong market demand lifts profitability

Revenues from our Becton, Dickinson & Company (BD) partnership were the key contributor to the performance in the third quarter with a growth of more than 30 percent. The long-standing markets continued to perform well, and markets launched over the past two years are now generating increasing order volumes, reflecting the cumulative impact of our cooperation and development efforts. The growth in the partnership with BD is the strongest we have seen in a decade.

Under the amended agreement with Zimmer Biomet, royalty generation is now more closely linked to underlying market performance. During the quarter we saw double-digit growth from royalties based on product sales driven by a growing market demand.

After a very strong second quarter, Wound Management had a softer third quarter, reflecting the inherent quarterly variability of the business as well as product phasing. Despite this Wound Management grew double digits organically over the first nine months, led by Hydrocyn aqua.

Because our business is built to run lean, our growth translated into strong underlying earnings in the third quarter. Adjusted EBITDA of 20 million SEK in the quarter and 55 million SEK over the last twelve months is our strongest profitability since the shift to a license-based business. Cash flow from operating activities was equally strong at SEK 14 million for the quarter, and 30 million SEK over the last twelve months, further demonstrating the strength and scalability of our business model.

Outlook: building on our momentum

We see good reasons for optimism. The progress with BD and our collaboration with Zimmer further strengthens our conviction in the long-term potential of the partnerships and their strategic importance to Bactiguard. We expect continued positive growth within our license business, supported by growing market traction and increasing demand in recently launched markets. Across our ongoing new partner dialogues, we see an interest that reinforces our confidence in the opportunities ahead and our efforts in business development remain firmly focused on advancing these discussions towards agreements. The long-term outlook for Wound Management remains equally positive. We believe that the underlying market dynamics, together with the continued expansion of Hydrocyn aqua, provide a solid foundation for future profitable growth. We remain committed to disciplined cost management while investing in the priorities that enable our long-term growth ambitions.

Christine Lind, CEO



Business model

Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company's unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices.

Bactiguard's infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.

Bactiguard operates through license partnerships with leading global MedTech companies that apply the infection prevention technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. Our license-focused business model is scalable with operational leverage.

Partnerships across three phases

Bactiguard's license revenues have three components: we receive revenues for coating and process development, we receive revenues for the right to use the coating technology on medical devices within a specific application and geographical area, and we receive royalties – a variable remuneration once the license partners' products reach the market. The revenues are generated across three partnership phases: application development, exclusivity and license.

An **application development partner** works in close collaboration with Bactiguard's R&D team exploring the application of our infection prevention technology to the partners' underlying device to enhance its performance. The nature of development work means that not every project will succeed, but the learnings are valuable for other application areas.

An **exclusivity partner** gets exclusive rights to apply our coating technology to a certain medical device but has no products in the market yet, for instance due to pending regulatory approvals, which can take time depending on the type of application and its classification.

A **license partner** has the right to market and sell medical devices with Bactiguard's coating technology, in a certain region or globally.

Not all partnerships will follow all three phases. An agreement with a partner can generate revenues from separate phases and components simultaneously.

Partnerships	Application area	Market
Becton, Dickinson & Company (BD)	Urinary catheters (Foley)	Exclusive global market rights (excl. China)
Zimmer Biomet	Trauma implants, ZNN Bactiguard	Non-exclusive global market rights (excl. Southeast Asia, China, India, and South Korea)
Well Lead Medical	Urinary catheters	Exclusive market rights in China



Development in the third quarter

Revenue

	*Revenue at constant currency		Reported revenue		
	Jul-Sep	Organic growth	Jul-Sep	Jul-Sep	Growth
MSEK	2026	%	2026	2025	%
Total license revenue	41.9	40.4	41.0	29.9	37.5
License partners	41.8	40.4	40.9	29.8	37.4
Exclusivity partners	-	-	-	-	-
Application development partners	0.1	79.4	0.1	0.1	-
Wound Management portfolio	14.3	-8.8	14.1	15.6	-9.9
BIP portfolio	-	-	-	0.0	-
Net sales	56.2	23.6	55.1	45.5	21.2
Other operating revenues	2.4	-17.7	3.3	2.9	14.8
Total revenue	58.5	21.1	58.4	48.4	20.8

*Constant-currency figures are translated using the prior-year average exchange rates.

Total revenue for the third quarter amounted to SEK 58.4 (48.4) million, an increase of SEK 10.0 million, corresponding to 20.8 percent. Adjusted for currency effects of SEK 0.1 million, revenue increased by 21.1 percent.

Net sales amounted to SEK 55.1 (45.5) million, an increase of SEK 9.7 million, corresponding to 21.2 percent. Adjusted for currency effects of SEK 1.1 million, net sales increased by 23.6 percent.

Total license revenue amounted to SEK 41.0 (29.9) million, an increase of SEK 11.1 million, corresponding to 37.5 percent. Adjusted for currency effects of SEK 0.9 million, total license revenues increased by 40.4 percent. Revenues from Becton Dickinson & Company (BD) amounted to SEK 37.6 (28.3) million, an increase of SEK 9.4 million, corresponding to 33.1 percent. Adjusted for currency effects of SEK -0.9 million, revenues from BD increased by 30.0 percent. The growth pertains to concentrate sales and royalties from positive development in both existing and new markets. Revenues from Zimmer Biomet amounted to SEK 3.4 (1.5) million, an increase of SEK 1.9 million, corresponding to 125.1 percent. Adjusted for currency effects of SEK -0.1 million, revenues from Zimmer increased by 117.6 percent. The increase pertains partly to the comparison period last year where no minimum royalties or fixed fees was recognized. In the quarter, we see positive double-digit growth in royalties from product sales.

Revenues from license partners amounted to SEK 40.9 (29.8) million, an increase of SEK 11.1 million, corresponding to 37.4 percent. Adjusted for currency effects of SEK 0.9 million, revenues from license partners increased by 40.4 percent.

Revenues from exclusivity partners amounted to SEK 0.0 (0.0) million.

Revenues from application development partners amounted to SEK 0.1 (0.1) million.

Revenues from Wound Management portfolio amounted to SEK 14.1 (15.6) million, a decrease of SEK 1.5 million, corresponding to 9.9 percent. Adjusted for currency effects of SEK 0.2 million, revenues from Wound Management portfolio decreased by 8.8 percent. The decrease mainly pertains to order phasing and we continue to expect Wound Management to deliver double-digit growth.

Revenues from the BIP portfolio amounted to SEK 0.0 (0.0) million. As planned, we do not expect any significant BIP revenues in 2026.

Other revenues amounted to SEK 3.3 (2.9) million, an increase of SEK 0.4 million, corresponding to 14.8 percent. Currency effects amounted to SEK 0.9 (0.8) million and the remaining revenue primarily relates to rent income.

Result

Costs for raw materials and consumables for the third quarter amounted to SEK -8.2 (-6.5) million, an increase of SEK 1.7 million, corresponding to 26.0 percent. Other external costs amounted to SEK -12.2 (-11.3) million. Personnel costs amounted to SEK -22.4 (-24.4) million, a decrease of SEK 2.0 million, corresponding to 8.1 percent. Other operating expenses are related to currency exchange losses/gains, which amounted to SEK -1.3



(-0.9) million. Total operating expenses (OPEX) amounted to SEK -35.9 (-36.6) million, a decrease of SEK 0.7 million, corresponding to 2.0 percent.

The operating profit amounted to SEK 6.8 (-6.4) million, an increase of SEK 13.2 million, corresponding to 205.6 percent. The improved result is mainly pertained to higher license revenue driven by positive development in both existing and new markets.

EBITDA for the third quarter amounted to SEK 17.5 (5.3) million, an increase of SEK 12.3 million. The EBITDA margin was 30.0 (10.9) percent.

Adjusted EBITDA for the third quarter amounted to SEK 20.0 (5.3) million with a margin of 34.3 (10.9) percent.

Depreciation and amortization amounted to SEK -10.7 (-11.7) million, a decrease of SEK 1.0 million, corresponding to 8.4 percent. Amortization of intangible assets amounted to SEK -6.5 (-7.1) million, attributable primarily to amortization of SEK -6.0 (-6.4) million related to Bactiguard's technology. Depreciation of tangible assets amounted to SEK -4.4 (-4.6) million, primarily attributable to depreciation on leasing of SEK -3.1 (-3.2) million.

Financial items amounted to SEK -0.8 (-2.5) million. Financial income amounted to SEK 1.2 (0.1) million. Financial expenses amounted to SEK -2.0 (-2.6) million which mainly pertained to interest expenses of SEK -1.7 (-2.1) million.

Current tax for the period amounted to SEK 0.0 (0.0) million. Change in deferred tax amounted to SEK 1.3 (1.4) million attributable to the intangible assets and leases, which is calculated at the Swedish tax rate of 20.6 percent. Income tax in foreign subsidiaries is calculated on the basis of a tax rate of 24.0 percent.

Net profit for the third quarter of 2026 amounted to SEK 7.3 (-7.5) million.

Development during the period January – September

Revenue

	*Revenue at constant currency					Reported revenue					
	Jan-Sep	Organic growth	Full year	RTM	Organic growth	Jan-Sep	Growth	Full year	RTM	Growth	
MSEK	2026	%	2025	2025/26	%	2026	2025	%	2025	2025/26	%
Total license revenue	104.0	0.7	163.3	159.9	-2.1	98.2	103.2	-4.9	152.3	147.3	-3.3
License partners	102.7	-0.4	163.0	158.3	-2.9	96.9	103.1	-6.0	152.0	145.8	-4.1
Exclusivity partners	-	-	-	-	-	-	-	-	-	-	-
Application development partners	1.3	-	0.3	1.6	434.2	1.3	0.1	-	0.3	1.5	-
Wound Management portfolio	55.5	13.9	63.1	69.8	10.6	53.4	48.7	9.7	62.7	67.5	7.5
BIP portfolio	-	-	0.9	-	-	-	0.9	-	0.9	-	-
Net sales	159.4	4.4	227.3	229.7	1.0	151.6	152.8	-0.8	215.9	214.7	-0.6
Other operating revenues	7.0	-32.5	9.6	9.1	-5.6	10.8	10.4	4.5	12.8	13.2	2.9
Total revenue	166.5	2.0	237.0	238.8	0.8	162.4	163.2	-0.5	228.8	227.9	-0.4

*Constant-currency figures are translated using the prior-year average exchange rates.

Total revenue for the period January to September amounted to SEK 162.4 (163.2) million, a decrease of SEK 0.8 million, corresponding to 0.5 percent. Adjusted for currency effects of SEK 4.0 million total revenue increased with 2.0 percent.

Net sales amounted to SEK 151.6 (152.8) million, a decrease of SEK 1.2 million, corresponding to 0.8 percent. Adjusted for currency effects of SEK 7.9 million, net sales increased by 4.4 percent.

Total license revenue amounted to SEK 98.2 (103.2) million, a decrease of SEK 5.0 million, corresponding to 4.9 percent. Adjusted for currency effects of SEK 5.8 million, total license revenues increased by 0.7 percent. Revenues from Becton Dickinson & Company (BD) amounted to SEK 86.9 (79.7) million, an increase of SEK 7.2 million, corresponding to 9.1 percent. Adjusted for currency effects of SEK 5.5 million, revenues from BD increased by 16.0 percent. Revenues from Zimmer Biomet amounted to SEK 11.2 (16.5) million, a decrease of SEK 5.3 million, corresponding to 32.0 percent. Adjusted for currency effects of SEK 0.4 million, revenues from Zimmer Biomet decreased by 29.9 percent. The higher level of Zimmer Biomet revenues during the same period 2025 pertained mainly to minimum royalties under the previous agreement with Zimmer Biomet.

Revenues from license partners amounted to SEK 96.9 (103.1) million, a decrease of SEK 6.2 million, corresponding to 6.0 percent. Adjusted for currency effects of SEK 5.8 million, revenues from license partners decreased by 0.4 percent.



Revenues from exclusivity partners amounted to SEK 0.0 (0.0) million.

Revenues from application development partners amounted to SEK 1.3 (0.1) million.

Revenues from Wound Management portfolio amounted to SEK 53.4 (48.7) million, an increase of SEK 4.7 million, corresponding to 9.7 percent. Adjusted for currency effects of SEK 2.1 million, revenues from Wound Management portfolio increased by 13.9 percent. This mainly pertains to growth of Hydrocyn aqua.

Revenues from the BIP portfolio amounted to SEK 0.0 (0.9) million. As planned, we do not expect any significant BIP revenues in 2026.

Other revenues amounted to SEK 10.8 (10.4) million, an increase of SEK 0.5 million, corresponding to 4.5 percent. Currency effects amounted to SEK 3.8 (2.9) million and the remaining revenue primarily relates to rent income.

Result

Costs for raw materials and consumables for the period January to September amounted to SEK -23.4 (-24.3) million, a decrease of SEK 0.9 million, corresponding to 3.7 percent. Other external costs amounted to SEK -44.0 (-43.1) million. Personnel costs amounted to SEK -70.8 (-70.9) million, a decrease of SEK 0.2 million, corresponding to 0.2 percent. Other operating expenses are related to currency exchange losses/gains, which amounted to SEK -5.6 (-5.8) million. In total operating expenses (OPEX) amounted to SEK -120.4 (-119.9) million, an increase of SEK 0.5 million, corresponding to 0.4 percent.

The operating loss amounted to SEK 8.6 (16.3) million, a decrease of SEK 7.7 million, corresponding to 47.3 percent. The improved result is mainly pertained to higher license revenue driven by positive development in both existing and new markets.

EBITDA for the period January to September amounted to SEK 24.3 (19.1) million, an increase of SEK 5.2 million. EBITDA margin was 15.0 (11.7) percent.

Adjusted EBITDA for the period January to September amounted to SEK 30.6 (19.1) million with a margin of 18.8 (11.7) percent.

Depreciation and amortization amounted to SEK -32.9 (-35.4) million, a decrease of SEK 2.5 million, corresponding to 7.1 percent. Amortization of intangible assets amounted to SEK -19.8 (-21.2) million, attributable primarily to amortization of SEK -18.1 (-19.1) million related to Bactiguard's technology. Depreciation of fixed assets amounted to SEK -13.1 (-14.2) million, primarily attributable to depreciation on leasing of SEK -9.2 (-9.7) million.

Financial items amounted to SEK -2.8 (-9.9) million. Financial income amounted to SEK 3.1 (0.1) million while financial expenses amounted to SEK -5.9 (-10.0) million which mainly pertained to interest expenses of SEK -5.1 (-6.7) million.

Current tax for the period amounted to SEK 0.0 (0.0) million. Change in deferred tax amounted to SEK 4.9 (5.9) million attributable to the intangible assets and leases, which is calculated at the Swedish tax rate of 20.6 percent. Income tax in foreign subsidiaries is calculated on the basis of a tax rate of 24.0 percent.

Net loss for the period January to September of 2026 amounted to SEK 6.5 (20.4) million.

Cash flow

Cash flow from operating activities for the quarter amounted to SEK 14.0 (-2.8) million and for the period January to September to SEK 18.7 (-13.2) million. Change in working capital for the quarter amounted to SEK -2.5 (-17.5) million and for the period January to September to SEK 4.5 (-21.4) million.

Cash flow from investing activities for the quarter amounted to SEK -0.2 (-2.5) million and for the period January to September to SEK -1.4 (-4.4) million.

Cash flow from financing activities for the quarter amounted to SEK -3.4 (-3.1) million and for the period January to September to -9.6 (-59.0), the 2025 number is mainly pertained to the amortization of SEK 51.0 million of the financing with SEB done in Q1 2025.

Cash flow for the quarter amounted to SEK 10.4 (-8.4) million and for the period January to September to SEK 7.7 (-76.5) million. Cash and cash equivalents at the end of the period of 30 September 2026 amounted to SEK 55.1 (37.4) million.



Financial position

Equity on 30 September 2026 amounted to SEK 313.3 (301.5) million and net debt to SEK 98.7 (128.7) million. Total assets on 30 September 2026 amounted to SEK 524.2 (544.6) million.

As of 30 September 2026, the parent company's liabilities with SEB amounted to SEK 120.0 (120.0) million. As of 30 September 2026, the approved overdraft facility from SEB of SEK 30 million was not utilized. Foreign subsidiaries had credit facilities amounting to SEK 8.7 (7.9) million, of which SEK 0.0 (1.6) million was utilized as of 30 September 2026.

Employees

Full-time equivalents in the Group during the period January to September averaged to 156 (161) FTE of which 105 (101) are women. On 30 September 2026, the number of full-time equivalents was 166 FTE.

The share and share capital

Bactiguard's B share is listed on Nasdaq Stockholm with the short name "BACTI B". The closing price for the B share was SEK 15.7 (20.2) on 30 September 2026 and the market capitalization amounted to SEK 561 (708) million.

The share capital in Bactiguard on 30 September 2026 amounted to SEK 0.9 (0.9) million divided into 715,000 Class C shares with one vote each (715,000 votes), 31,043,885 Class B shares with one vote each (31,043,885 votes) and 4,000,000 Class A shares with ten votes each (40,000,000 votes). The total number of shares and votes in Bactiguard on 30 September 2026 was 35,758,885 shares and 71,758,885 votes.

Ownership

Shareholders	No. of A shares	No. of B shares	No. of C shares	Total number	% of capital	% of votes
TomBact AB ¹	4,000,000	11,447,615		15,447,615	43.2	71.7
Nordea Funds AB		3,721,094		3,721,094	10.4	5.2
STÅHLBERG JAN INGE		3,605,150		3,605,150	10.1	5.0
FJÄRDE AP-FONDEN		3,475,992		3,475,992	9.7	4.8
Handelsbanken FonderAB		1,796,925		1,796,925	5.0	2.5
FörsäkringsaktiebolagetAvanza Pension		849,326		849,326	2.4	1.2
Lancelot AssetManagement AB		600,000		600,000	1.7	0.8
SEB Funds AB		437,797		437,797	1.2	0.6
SEB LIFEINTERNATIONALASSURANCE		393,000		393,000	1.1	0.6
Lind Christine Anne		389,500		389,500	1.1	0.5
Total, major shareholders	4,000,000	26,716,399		30,716,399	85.9	93.0
Total, others		4,327,486		4,327,486	12.1	6.0
Treasury shares			715,000	715,000	2.0	1.0
Total number of shares	4,000,000	31,043,885	715,000	35,758,885	100.0	100.0

¹ Company controlled by Thomas von Koch.

Per 30 September 2026 Bactiguard had 2,692 (2,885) shareholders.

Key events

Key events during the quarter

The Board of Bactiguard Holding AB has on the 8 July 2026, pursuant to authorisations granted by the annual general meeting on 19 May 2026, resolved on a directed issue and immediate repurchase of 715,000 Class C shares. The measures are intended to ensure the Company's ability to deliver shares to participants in the share-based long-term incentive plan 2026 ("LTIP 2026") adopted by the annual general meeting if, and to the extent that, the relevant performance conditions are satisfied during the plan's performance measurement period.

The number of shares and votes in Bactiguard Holding AB has increased during July 2026 as a result of the new issue of Class C shares to secure the Company's commitments under the LTIP 2026. All Class C shares have been repurchased by the Company and will be converted into Class B shares in connection with the delivery of Class B shares to participants under the terms of LTIP 2026.



TomBact AB acquired 2,000,000 Class A shares and 4,106,957 Class B shares in Bactiguard Holding AB from Christian Kinch on 27 August 2026. The acquired holding corresponds to approximately 17 percent of the total number of shares and approximately 34 percent of the voting rights in the Company. The transaction was completed after market close at a premium of 56 percent to Bactiguard Holding AB's closing share price on 27 August 2026.

Bactiguard Holding AB announced on the 17 September 2026 the release of previously unpublished data on its noble metal technology that highlight its distinct and durable properties for orthopedic implants. The new data were presented at the 37th Annual Congress of the International Society for Technology in Arthroplasty (ISTA).

Key events after the end of the quarter

No key events after the end of the quarter.

Financial targets

The company's financial targets relate to growth and profitability and are expected to be delivered by year-end 2030. The financial and strategic targets should not be perceived as a forecast but rather reflect what Bactiguard's Board of Directors and Executive Management consider to be reasonable mid-term expectations given the sharpened license focused strategy.

Revenues: deliver revenues of at least SEK 600 million by year-end 2030

EBITDA: deliver an EBITDA of at least SEK 200 million by year-end 2030

Partnership development: have at least ten application areas in either exclusivity partnerships or license partnerships by year-end 2030

Other information

Accounting and valuation principles

The consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (IFRS). The interim report has been prepared in accordance with IAS 34 Interim Reporting and the Annual Accounts Act. Disclosures in accordance with IAS 34 Interim Reporting are submitted both in notes and elsewhere in the interim report. The parent company's financial statements have been prepared in accordance with the Annual Accounts Act and the Financial Reporting Board's recommendation, RFR 2 Accounting for Legal Entities.

Accounting and valuation principles are stated in the annual report 2025. The accounting principles are unchanged from previous periods.

Segment reporting

An operating segment is a component of an entity that engages in business activities from which it may derive revenues and incur expenses, whose operating results are regularly reviewed by the chief operating decision maker and for which there is separate financial information. The company's reporting of operating segments is consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function that assesses the operating segment performance and decides how to allocate resources. The company has determined that the Group's executive management constitutes of the chief operating decision maker. The company is considered in its entirety to operate within one business segment.

Parent company

During the period, the parent company has received compensation for services and interest in its receivables from group companies. No investments were made during the period.

Risk factors

Companies within the Group are exposed to various types of risk through their activities. Bactiguard continually engages in a process of identifying all risks that may arise and assessing how each of these risks shall be managed. The Group is working to create an overall risk management program that focuses on minimizing potential adverse effects on the company's financial results. The company is primarily exposed to financial risks, market risks, and operational risks. A description of these risks can be found on page 14-15 and 57-59 in the annual report 2025.



The geopolitical situation and macro trends

In addition to identified risks, the macro situation and its impact is continuously monitored. The global healthcare challenges have a significant impact on society. The need for more efficient and safe healthcare is driven by both economic and demographic developments, as well as increased political unrest, conflicts, wars, and natural disasters. Particularly prominent are healthcare-associated infections and antimicrobial resistance where we see an increased interest in infection prevention.

Bactiguard does not have suppliers in or sales to any of Russia, Belarus, or Ukraine. However, the global economy is affected by the situation of the war, and we follow developments closely and continuously evaluate the operational and financial effects as the global situation may change and affect the company's financial position. Bactiguard has a subsidiary in Israel. We are closely following the developments there and our primary focus is to ensure the staff's well-being and security. We make the assessment that the conflict in Israel will have a negligible effect on the group's result and financial position.

The global macroeconomic environment remains uncertain, with developments in inflation, interest rates, currency fluctuations and economic growth potentially affecting the company's operations and financial performance. Changes in cost levels may impact profitability, as increased costs cannot always be fully passed on to customers. Interest rate movements may affect the financing costs. Bactiguard has substantial USD exposure in the license business and fluctuations in exchange rates may impact the result, see the annual report 2025. The company does not hedge its currency exposure. Developments are monitored closely, given the rapidly evolving landscape.



Group consolidated income statement

TSEK	Note	Jul-Sep		Jan-Sep		Full year	RTM
		2026	2025	2026	2025	2025	2025/26
Revenues	1						
Net sales		55,115	45,464	151,565	152,753	215,918	214,730
Other operating income		3,313	2,885	10,821	10,451	12,849	13,219
Total		58,428	48,349	162,386	163,204	228,767	227,949
Change in inventory of finished goods and products in progress		3,144	26	5,706	47	2,618	8,277
Raw materials and consumables		-8,181	-6,493	-23,397	-24,297	-33,883	-32,983
Other external expenses		-12,208	-11,305	-44,005	-43,140	-51,595	-52,460
Personnel costs		-22,402	-24,368	-70,770	-70,934	-95,376	-95,212
Depreciation and amortization		-10,723	-11,712	-32,898	-35,405	-47,077	-44,570
Other operating expenses		-1,255	-940	-5,639	-5,823	-6,776	-6,592
Total		-51,625	-54,792	-171,003	-179,552	-232,089	-223,540
Operating profit/loss		6,803	-6,443	-8,616	-16,348	-3,322	4,409
Profit/loss from financial items							
Financial income		1,202	87	3,136	108	1,392	4,420
Financial expenses		-2,010	-2,601	-5,945	-10,008	-12,183	-8,120
Total		-808	-2,514	-2,809	-9,900	-10,791	-3,700
Profit/loss before tax		5,995	-8,957	-11,425	-26,248	-14,113	709
Current tax	1	-	-	46	-	-1,019	-973
Deferred tax		1,268	1,441	4,886	5,893	7,288	6,281
NET PROFIT/LOSS FOR THE PERIOD		7,264	-7,516	-6,493	-20,355	-7,844	6,017
Attributable to:							
The parent company's shareholders		7,264	-7,516	-6,493	-20,355	-7,844	6,017
Earnings per share before dilution, SEK		0.25	-0.21	-0.14	-0.59	-0.22	0.22
Earnings per share after dilution, SEK		0.25	-0.21	-0.14	-0.59	-0.22	0.22

Condensed statement of comprehensive income

TSEK	Note	Jul-Sep		Jan-Sep		Full year	RTM
		2026	2025	2026	2025	2025	2025/26
Net profit/loss for the period		7,264	-7,516	-6,493	-20,355	-7,844	6,017
Other comprehensive income:							
Items that will not be reclassified to profit or loss for the year		-	-	-	-	-	-
Items that will be reclassified to profit or loss for the year							
Translation differences		1,376	-367	4,648	-6,507	-5,565	5,590
Other comprehensive income, after tax		1,376	-367	4,648	-6,507	-5,565	5,590
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		8,639	-7,882	-1,846	-26,861	-13,409	11,607
Attributable to:							
The parent company's shareholders		8,639	-7,882	-1,846	-26,861	-13,409	11,607
Number of shares at the end of period ('000)		35,759	35,044	35,759	35,044	35,044	35,759
Weighted average number of shares ('000)		35,044	35,044	35,044	35,044	35,044	35,044



Group condensed statement of financial position

TSEK	Note	2026-09-30	2025-09-30	2025-12-31
ASSETS				
Non-current assets				
Intangible fixed assets				
Goodwill		251,498	248,320	248,817
Technology		4,649	29,111	22,771
Brands		25,579	25,579	25,579
Customer relationships		1,505	2,789	2,462
Capitalized development costs		34	792	517
Patent		485	682	605
Total		283,750	307,273	300,751
Tangible assets				
Right of use lease assets		30,838	41,839	39,684
Buildings		24,313	22,427	22,992
Leasehold improvements		17,253	18,851	18,194
Machinery and other technical plant		4,194	5,180	5,047
Equipment, tools and installations		7,454	7,098	7,426
Total		84,052	95,395	93,343
Financial assets				
Other non-current receivables		2,873	2,859	2,857
Total		2,873	2,859	2,857
Deferred tax assets		28,748	23,437	23,941
Total non-current assets		399,423	428,964	420,892
Current assets				
Inventory		29,500	27,138	21,881
Accounts receivable		20,053	28,861	35,757
Other current receivables	2	9,185	10,988	10,197
Prepaid expenses and accrued income		11,024	11,267	12,075
Cash and cash equivalents		55,053	37,422	44,261
Total current assets		124,815	115,676	124,171
TOTAL ASSETS		524,238	544,640	545,063
EQUITY AND LIABILITIES				
Equity attributable to shareholders of the parent				
Share capital		894	876	876
Translation reserve		3,207	-2,383	-1,441
Other capital contribution		930,478	930,680	930,680
Retained earnings including net profit/loss for the period		-621,253	-627,693	-615,182
Total equity		313,326	301,481	314,933
Non-current liabilities				
Liabilities to credit institutions		119,267	120,398	119,373
Leasing liabilities		20,018	32,192	29,472
Provisions		5,257	5,257	6,966
Other long-term liabilities		-	92	-
Total non-current liabilities		144,542	157,939	155,811
Current liabilities				
Leasing liabilities		14,466	13,530	14,079
Accounts payable		10,562	15,137	17,750
Provisions		3,452	16,297	7,391
Other current liabilities	2	1,472	1,647	2,013
Accrued expenses and prepaid income		36,418	38,609	33,086
Total current liabilities		66,370	85,220	74,319
TOTAL LIABILITIES		210,912	243,159	230,130
TOTAL EQUITY AND LIABILITIES		524,238	544,640	545,063



Group condensed statement of changes in equity

TSEK	Share capital	Other capital contribution	Reserves	Retained earnings including net profit/loss for the period	Total equity
Opening balance 2025-01-01	876	930,680	4,124	-607,338	328,342
Net profit/loss for the period	-	-	-	-20,355	-20,355
<i>Other comprehensive income:</i>					
Translation differences	-	-	-6,507	-	-6,507
Total comprehensive income after tax	-	-	-6,507	-20,355	-26,862
Closing balance 2025-09-30	876	930,680	-2,383	-627,693	301,480

Opening balance 2026-01-01	876	930,680	-1,441	-615,182	314,933
Net profit/loss for the period	-	-	-	-6,493	-6,493
<i>Other comprehensive income:</i>					
Translation differences	-	-	4,648	-	4,648
Total comprehensive income after tax	-	-	4,648	-6,493	-1,845
New issue	18	-	-	-	18
Repurchase of own shares	-	-	-	-18	-18
Share-based payments	-	-	-	238	238
Total transactions with shareholders	18	-	-	220	238
Closing balance 2026-09-30	894	930,680	3,207	-621,455	313,326



Group condensed statement of cash flows

TSEK	Note	Jul-Sep		Jan-Sep		Full year	RTM
		2026	2025	2026	2025	2025	2025/26
Net profit/loss for the period		7,263	-7,515	-6,494	-20,355	-7,844	6,017
Adjustments for depreciation and amortization and other non-cash items		9,253	22,197	20,646	28,573	33,751	25,824
Increase/decrease inventory		-2,745	1,422	-7,204	2,422	7,631	-1,995
Increase/decrease accounts receivable		1,531	-1,388	14,322	-4,599	-13,702	5,219
Increase/decrease other current receivables		858	5,055	2,048	4,063	4,047	2,032
Increase/decrease accounts payable		572	-5,723	-7,188	-7,788	-5,175	-4,575
Increase/decrease other current liabilities		-2,763	-16,845	2,567	-15,492	-20,195	-2,136
<i>Cash flow from changes in working capital</i>		<i>-2,547</i>	<i>-17,479</i>	<i>4,545</i>	<i>-21,393</i>	<i>-27,394</i>	<i>-1,456</i>
Cash flow from operating activities		13,969	-2,794	18,697	-13,174	-1,487	30,386
Investments in intangible assets		-	-	-	-	-	-
Investments in tangible assets		-191	-2,461	-1,440	-4,366	-5,720	-2,794
Cash flow from investing activities		-191	-2,461	-1,440	-4,366	-5,720	-2,794
Amortization of leasing liability		-3,229	-3,545	-9,453	-8,502	-11,223	-12,174
Amortization of loan		-	-	-	-52,048	-51,748	300
Change in bank overdraft		-185	420	-106	1,553	228	-1,431
New issue		18	-	18	-	-	18
Repurchase of own shares		-18	-	-18	-	-	-18
Cash flow from financing activities		-3,414	-3,125	-9,559	-58,996	-62,743	-13,306
Cash flow for the period		10,364	-8,380	7,698	-76,538	-69,949	14,287
Cash and cash equivalents at the beginning of the period		43,524	46,100	44,261	116,727	116,727	37,422
Exchange difference in cash and cash equivalents		1,164	-298	3,093	-2,767	-2,517	3,343
Cash and cash equivalents at end of period		55,053	37,422	55,053	37,422	44,261	55,053



Condensed parent company income statement

TSEK	Note	Jul-Sep		Jan-Sep		Full year	RTM
		2026	2025	2026	2025	2025	2025/26
Net sales		788	660	1,435	1,986	2,833	2,282
Total		788	660	1,435	1,986	2,833	2,282
Other external expenses		-902	-686	-2,851	-2,715	-3,728	-3,864
Personnel costs		-742	-740	-2,224	-2,291	-3,032	-2,965
Total		-1,644	-1,426	-5,075	-5,006	-6,760	-6,829
Operating profit/loss		-856	-766	-3,640	-3,020	-3,928	-4,548
Financial income		2,757	3,014	8,373	9,773	12,670	11,270
Financial expenses		-1,642	-1,712	-4,659	-5,566	-7,202	-6,295
Total		1,115	1,302	3,714	4,207	5,468	4,975
Income after financial items		258	536	73	1,187	1,541	427
Deferred tax		-	-	-	-	-	-
Net profit/loss for the period		258	536	73	1,187	1,541	427

The parent company presents no separate statement of comprehensive income since the company has no items in 2026 or 2025 recognized in other comprehensive income. Net profit/loss for the period for the parent company thereby also constitutes of the comprehensive income for the period.



Condensed parent company balance sheet

TSEK	Note	2026-09-30	2025-09-30	2025-12-31
ASSETS				
<i>Non-current assets</i>				
Financial assets				
Shares in subsidiaries		635,429	635,191	635,191
Receivables from group companies		282,677	292,723	290,711
Deferred tax assets		15,255	15,255	15,255
Total non-current assets		933,360	943,169	941,157
<i>Current assets</i>				
Current receivables				
Other current receivables		-7	729	1,713
Prepaid expenses and accrued income		74,540	63,677	66,455
Total		74,534	64,406	68,168
Cash and bank equivalents		2,934	3,193	1,764
Total current assets		77,467	67,599	69,932
TOTAL ASSETS		1,010,828	1,010,768	1,011,089
EQUITY & LIABILITIES				
<i>Equity</i>				
Restricted equity				
Share capital		894	876	876
Total restricted equity		894	876	876
Non-restricted equity				
Retained earnings		-23,405	-25,166	-25,166
Non-restricted share premium		727,767	727,969	727,969
Net profit/loss for the period		73	1,187	1,541
Total non-restricted equity		704,435	703,990	704,344
Total equity		705,329	704,867	705,220
<i>Non-current liabilities</i>				
Liabilities to credit institutions		120,000	120,000	120,000
Total non-current liabilities		120,000	120,000	120,000
<i>Current liabilities</i>				
Liabilities to group companies		184,000	184,000	184,000
Accounts payable		-20	220	297
Other current liabilities		128	130	133
Accrued expenses and prepaid income		1,391	1,552	1,439
Total current liabilities		185,499	185,901	185,869
Total liabilities		305,499	305,901	305,869
TOTAL EQUITY AND LIABILITIES		1,010,828	1,010,768	1,011,089



Definitions of alternative key performance indicators

Bactiguard presents certain financial measures in its annual report that have not been defined in line with IFRS (referred to as alternative key performance indicators as set forth in the ESMA guidelines). It is the opinion of the company that these measures provide useful supplementary information to investors and the company's management as they allow for the evaluation of the company's performance. Since not all companies calculate the measures in the same way, these are not always comparable to measures used by other companies. These performance measures should therefore not be considered a substitute for measures as defined under IFRS.

The definitions and tables below describe how the performance measures are calculated. The measures are alternative in accordance with ESMA's guidelines unless otherwise stated.

EBITDA

EBITDA presents the company's earning capacity from ongoing operations irrespective of capital structure and tax situation. The key figure is used to facilitate comparisons with other companies in the same industry. The company considers this performance measure to be the most relevant, since the company's technology is depreciated by large amounts, which does not impact cash flow negatively. Bactiguard's patented, unique technology can be applied to a broad range of products in the licensing business.

The company defines EBITDA as operating profit/loss excluding depreciation and amortization of tangible and intangible assets.

TSEK	Jul-Sep		Jan-Sep		Full year	RTM
	2026	2025	2026	2025	2025	2025/26
Operating profit/loss	6,801	-6,443	-8,617	-16,348	-3,322	4,409
Depreciation	10,723	11,712	32,898	35,405	47,077	44,570
EBITDA	17,524	5,269	24,281	19,057	43,755	48,979

EBITDA margin

Presents the company's earning capacity from ongoing operations, irrespective of capital structure and tax situation, in relation to revenues. The key figure is used to facilitate analysis of the company's result in comparison with comparable companies.

TSEK	Jul-Sep		Jan-Sep		Full year	RTM
	2026	2025	2026	2025	2025	2025/26
EBITDA	17,524	5,269	24,281	19,057	43,755	48,979
Revenues	58,428	48,349	162,386	163,204	228,767	227,949
EBITDA margin %	30.0	10.9	15.0	11.7	19.1	21.5

Adjusted EBITDA

Adjusted EBITDA is presented as an alternative performance measure to illustrate the underlying operating performance by excluding items affecting comparability. A reconciliation to EBITDA is provided below. The Group expects to incur non-recurring costs related to the EU Medical Device Regulations (MDR) during 2026 and 2027. These costs are not considered representative of the underlying operating performance as they do not form part of the Group's ongoing core operations and are therefore considered non-recurring. To provide a more comparable view of performance, the Group therefore also presents adjusted EBITDA and adjusted EBITDA margin excluding these costs.

TSEK	Jul-Sep		Jan-Sep		Full year	RTM
	2026	2025	2026	2025	2025	2025/26
Operating profit/loss	6,801	-6,443	-8,617	-16,348	-3,322	4,409
Depreciation	10,723	11,712	32,898	35,405	47,077	44,570
EBITDA	17,524	5,269	24,281	19,057	43,755	48,979
Adjustments for MDR-costs	2,511	-	6,233	-	-	6,305
Adjusted EBITDA	20,035	5,269	30,586	19,057	43,755	55,284



Adjusted EBITDA margin

Presents the company's adjusted, as defined above, earning capacity from ongoing operations, irrespective of capital structure and tax situation, in relation to revenues.

TSEK	Jul-Sep		Jan-Sep		Full year	RTM
	2026	2025	2026	2025	2025	2025/26
Adjusted EBITDA	20,035	5,269	30,586	19,057	43,755	55,284
Revenues	58,428	48,349	162,386	163,204	228,767	227,949
Adjusted EBITDA margin %	34.3	10.9	18.8	11.7	19.1	24.3

Net debt

Net debt is a measure used to describe the Group's indebtedness and its ability to repay its debt with cash generated from the Group's operating activities if the debts matured today. The company considers this key figure interesting for creditors who want to understand the Group's debt situation.

The company defines net debt as interest-bearing liabilities minus cash and cash equivalents at the end of the period.

TSEK	Jan-Sep		Full year
	2026	2025	2025
Non-current liabilities to credit institutions	119,267	120,398	119,373
Long-term lease debt	20,018	32,192	29,472
Short-term lease debt	14,466	13,530	14,079
Interest-bearing debt	153,751	166,120	162,924
Cash and cash equivalents	55,053	37,422	44,261
Net debt	98,698	128,698	118,663

Equity ratio

Equity ratio is a measure the company considers important for creditors who want to understand the company's long-term ability to pay. The company defines equity ratio as equity and untaxed reserves (less deferred tax), in relation to the balance sheet total.

TSEK	Jan-Sep		Full year
	2026	2025	2025
Equity	313,326	301,481	314,933
Balance sheet total	524,238	544,640	545,063
Equity ratio, %	59.8	55.4	57.8

Cash flow from operating activities per share

Cash flow per share calculated as the cash flow from operating activities divided by the average number of shares outstanding during the period. The key figure is presented because it is used by analysts and other stakeholders to evaluate the company – it shows operating cash flow per share.

Profit/loss from financial items

Financial income minus financial expenses. Direct reconciliation against financial report is possible.

RTM/Rolling 12 months

This performance measure implies the twelve months before and including a certain date.



Note 1 Revenue distribution

TSEK	Jul-Sep		Jan-Sep		Full year	RTM
	2026	2025	2026	2025	2025	2025/26
License partners	40,897	29,771	96,894	103,103	152,030	145,821
Exclusivity partners	-	-	-	-	-	-
Application development partners	128	76	1,278	118	294	1,454
Wound Management portfolio	14,091	15,633	53,394	48,674	62,736	67,456
BIP portfolio	-	-15	-	858	858	-
Total	55,115	45,464	151,565	152,753	215,918	214,730
Time for revenue recognition						
Performance commitment is met at a certain time	54,988	45,389	150,288	152,635	215,624	213,276
Performance commitment is met during a period of time	128	76	1,278	118	294	1,454
Total	55,115	45,464	151,565	152,753	215,918	214,730

Note 2 Financial assets and liabilities at fair value

The table below shows the breakdown of financial assets and financial liabilities recognized at fair value in the consolidated balance sheet. Distribution of how fair value is determined is based on three levels.

Level 1: according to prices quoted on an active market for the same instrument.

Level 2: based on directly or indirectly observable market data not included in level 1.

Level 3: based on input data that is not observable on the market.

For description of how fair values have been calculated, see annual report 2025, note 4. Fair value of financial assets and liabilities are estimated to be substantially consistent with posted values. The balance sheet contains receivables and liabilities from the business that are held to maturity. These are reported at amortized cost, which also constitutes an approximation to fair value.

Note 3 Share-based payments

At the Annual General Meeting held on 19 May 2026, a new long-term share-based incentive programme, LTIP 2026, was approved. The programme is directed at the CEO, senior executives, managers and selected key employees within the Group. The purpose of the programme is to promote long-term commitment and align the interests of participants with those of the Company's shareholders.

LTIP 2026 is accounted for as an equity-settled share-based payment arrangement in accordance with IFRS 2, Share-based Payment. Participants have been granted performance share rights which, subject to continued employment and the fulfilment of predetermined performance conditions, entitle participants to receive shares in Bactiguard Holding AB without consideration.

The vesting period runs from July 2026 to June 2029. Vesting is conditional upon continued employment throughout the vesting period and achievement of performance targets linked to the Group's adjusted EBITDA.

During the third quarter, the Company issued and immediately repurchased 715,000 Class C shares in order to secure future share deliveries under LTIP 2026. The repurchased shares are held by the Company and are intended to secure future share deliveries in accordance with the programme's terms.

The share rights granted under LTIP 2026 correspond to a maximum dilution effect of approximately 2.0 per cent of the total number of shares in the Company.

The grant date fair value of each performance share right was determined to SEK 16.65.

During the period, an expense of SEK 0.2 million (0.0) was recognised in relation to LTIP 2026, excluding social security contributions.



Quarterly information

TSEK	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	RTM 25/26
License partners	40,897	31,751	24,246	48,927	29,771	34,080	145,821
Exclusivity partners	-	-	-	-	-	-	-
Application development partners	128	263	887	176	83	-15	1,454
Wound Management portfolio	14,091	21,988	17,315	14,062	15,633	13,840	67,456
BIP portfolio	-	-	-	-	-15	324	-
Other operating revenues	3,313	3,051	4,457	2,398	2,878	3,887	13,219
Total revenue	58,428	57,053	46,905	65,563	48,349	52,115	227,949
EBITDA	17,524	2,632	4,125	24,698	5,269	4,379	48,979
EBITDA margin (%)	30.0	4.6	8.8	37.7	10.9	8.4	21.5
Adjusted EBITDA	20,035	5,630	4,920	24,698	5,269	4,379	55,283
Adjusted EBITDA margin (%)	34.3	9.9	10.5	37.7	10.9	8.4	24.3
EBIT	6,801	-8,250	-7,168	13,026	-6,443	-7,295	4,409
Net profit/loss for the period	7,262	-8,194	-5,562	12,511	-7,516	-8,111	6,017
Earnings per share before dilution, SEK	0.25	-0.23	-0.16	0.36	-0.21	-0.24	0.22
Earnings per share after dilution, SEK	0.25	-0.23	-0.16	0.36	-0.21	-0.24	0.22
Operating cash flow	13,969	12,442	-7,433	11,689	-2,794	1,727	30,667
Operating cash flow per share, SEK	0.39	0.36	-0.21	0.33	-0.08	0.05	0.87
Net debt	98,698	113,567	125,957	118,663	128,698	123,364	98,698
Total shares (pcs)	35,043,885	35,043,885	35,043,885	35,043,885	35,043,885	35,043,885	35,043,885



Signatories of the report

The Board of Directors and the CEO certify that the interim report, to the best of their knowledge, provides a fair overview of the parent company's and the Group's operations, financial position and results and describes the material risks and uncertainties faced by the parent company and the companies included in the Group.

Stockholm 22 October 2026

Thomas von Koch
Chairperson of the Board

Richard Kuntz
Board Member

Anna Martling
Board Member

Magdalena Persson
Board Member

Jan Ståhlberg
Board Member

Christine Lind
CEO

This interim report has been reviewed by the company auditors.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below on 22 October 2026, at 07:00 a.m. CET.

This is a translation of the Swedish Interim report. In the event of any discrepancy, the Swedish version applies.



About Bactiguard

Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company's unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices.

Bactiguard's infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.

Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. The company also has a portfolio of wound management products.

Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.

Read more about Bactiguard bactiguard.com

Follow Bactiguard on [LinkedIn](#)

Financial calendar

4 February 2027	Year-end report 1 January – 31 December 2026
31 March 2027	Annual Report 2026
22 April 2027	Interim report first quarter 1 January – 31 March 2027
13 July 2027	Interim report second quarter 1 April – 30 June 2027
21 October 2027	Interim report third quarter 1 July – 30 September 2027

Contacts

For additional information, please contact:
Patrick Bach, CFO: +46 8 440 58 80